Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI).

Full DD Report for BCLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: BCLI)

BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell ther...
Source: GlobeNewswire
Date: November, 07 2018 08:00
BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2018 Results - Earnings Call Transcript
BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2018 Earnings Conference Call October 29, 2018 8:30 AM ET Executives Joseph Petroziello – Vice President-Scientific and Corporate Communications Chaim Lebovits – President and Chief Executive Officer Eyal Rubin – Ex...
Source: SeekingAlpha
Date: October, 29 2018 14:14
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress for NurOwn ® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn ® in a Second Clinical Indication Conference Call and Webcast Today at 8:30am Eastern T...
Source: GlobeNewswire
Date: October, 29 2018 08:00
BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwri...
Source: GlobeNewswire
Date: September, 05 2018 11:35
BrainStorm Appoints Arturo Araya as Chief Commercial Officer
Mr. Araya was Global Head of Commercial of Novartis Cell & Gene Therapies Unit Appointment strengthens leadership team with nearly 20 years of global pharmaceutical marketing and commercialization experience NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NE...
Source: GlobeNewswire
Date: September, 04 2018 08:00
BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference
NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C. Wainwrig...
Source: GlobeNewswire
Date: August, 29 2018 08:00
BrainStorm's late-stage study of NurOwn in ALS to continue as planned; shares up 4% premarket
Thinly traded nano cap BrainStorm Cell Therapeutics (NASDAQ: BCLI ) is up  4%  premarket on average volume on the heels of its announcement that the Phase 3 clinical trial evaluating its NurOwn cell therapy in patients with amyotrophic lateral sclerosis (ALS) will continue as pla...
Source: SeekingAlpha
Date: August, 23 2018 09:00
BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS
NEW YORK, and PETACH TIKVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DS...
Source: GlobeNewswire
Date: August, 23 2018 08:20
BrainStorm Announces Grant of a New European Patent for NurOwn®
NEW YORK and PETACH TIKVAH, Israel, July  25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a...
Source: PR Newswire
Date: July, 25 2018 09:03
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2018 Results - Earnings Call Transcript
Start Time: 08:30 End Time: 08:45 BrainStorm Cell Therapeutics Inc. (BCLI) Q2 2018 Earnings Conference Call July 23, 2018, 08:30 AM ET Executives Chaim Lebovits - CEO Eyal Rubin - CFO Ralph Kern - CMO & COO Analysts Caroline Palomeque - Maxim Group David Bautz - Z...
Source: SeekingAlpha
Date: July, 23 2018 10:33

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-123.113.123.15753.0739,887
2018-12-113.053.103.152.980142,813
2018-12-103.053.003.052.9267,983
2018-12-073.053.053.103.0515,366
2018-12-062.993.033.062.9547,144

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-123,1706,90145.9354Short
2018-12-111,36310,32113.2061Cover
2018-12-1015,43016,82891.6924Short
2018-12-073,2194,69368.5915Short
2018-12-0613,17517,33675.9979Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BCLI.


About BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

Logo for BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

BrainStorm Cell Therapeutics Inc. is a clinical stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company s current primary targets are Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig s disease and Parkinson s disease PD . These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.

 

 

 

Current Management

  • Anthony Fiorino / CEO
  • Chaim Lebovits / President
  • Liat Sossover / CFO
  • Adrian Harel / IR
  • Irit Arbel /
  • Mordechai Friedman /
  • Alon Pinkas /
  • Chen Schor /
  • Dr. Robert Shorr /
  • Malcolm Taub /

Current Share Structure

  • Market Cap: $61,977,630 - 03/20/2018
  • Issue and Outstanding: 19,070,040 - 03/06/2018

 


Recent Filings from (NASDAQ: BCLI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018

 

 


Daily Technical Chart for (NASDAQ: BCLI)

Daily Technical Chart for (NASDAQ: BCLI)


Stay tuned for daily updates and more on (NASDAQ: BCLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BCLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BCLI and does not buy, sell, or trade any shares of BCLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/